Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) (Measure Up 1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03569293
Recruitment Status : Active, not recruiting
First Posted : June 26, 2018
Last Update Posted : October 8, 2020
Sponsor:
Information provided by (Responsible Party):
AbbVie

Tracking Information
First Submitted Date  ICMJE June 14, 2018
First Posted Date  ICMJE June 26, 2018
Last Update Posted Date October 8, 2020
Actual Study Start Date  ICMJE August 13, 2018
Estimated Primary Completion Date January 20, 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: May 20, 2020)
  • Percentage of Participants Achieving at least a 75% Reduction in Eczema Area and Severity Index (EASI 75) from Baseline [ Time Frame: At Week 16 ]
    The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of atopic dermatitis (AD).
  • Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of 0 or 1 with at least two Grades of Reduction from Baseline [ Time Frame: At Week 16 ]
    The vIGA-AD is a validated assessment instrument used in clinical studies to rate the severity of AD globally.
Original Primary Outcome Measures  ICMJE
 (submitted: June 22, 2018)
  • Proportion of participants achieving at least a 75% reduction in Eczema Area and Severity Index (EASI 75) [ Time Frame: At Week 16 ]
    The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of atopic dermatitis (AD).
  • Proportion of participants achieving validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of 0 or 1 with at least two grades of reduction [ Time Frame: At Week 16 ]
    The vIGA-AD is a validated assessment instrument used in clinical studies to rate the severity of AD globally.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: May 20, 2020)
  • Percentage of Participants Achieving an Improvement (Reduction) in Worst Pruritus Numerical Rating Scale (NRS) ≥ 4 from Baseline for Participants with Worst Pruritus NRS ≥ 4 at Baseline [ Time Frame: Up to Week 16 ]
    The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period.
  • Percentage of Participants Achieving EASI 90 [ Time Frame: At Week 16 ]
    The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD.
  • Percentage of Participants Achieving EASI 75 [ Time Frame: At Week 2 ]
    The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of atopic dermatitis (AD).
  • Percentage of Participants Achieving an Improvement (Reduction) in Worst Pruritus Numerical Rating Scale (NRS) ≥ 4 for Participants with Worst Pruritus NRS ≥ 4 at Baseline and Randomized to Dose A [ Time Frame: At Day 2 ]
    The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period.
  • Percentage of Participants Achieving an Improvement (Reduction) in Worst Pruritus Numerical Rating Scale (NRS) ≥ 4 for Participants with Worst Pruritus NRS ≥ 4 at Baseline and Randomized to Dose B [ Time Frame: At Day 3 ]
    The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a daily recall period.
  • Percentage of Participants Experiencing a Flare [ Time Frame: Up to Week 16 ]
    Defined as clinically meaningful worsening in EASI.
  • Percentage of Participants Achieving an Improvement (Reduction) in Atopic Dermatitis Impact Scale (ADerm-IS) Sleep Domain Score >= 12 (Minimal Clinically Important Difference (MCID)) from Baseline [ Time Frame: At Week 16 ]
    This is assessed for participants with ADerm-IS sleep domain score >= 12 (MCID) at baseline.
  • Percentage of Participants Achieving an Improvement (Reduction) in Atopic Dermatitis Symptom Scale (ADerm-SS) Skin Pain Score >= 4 (MCID) from Baseline [ Time Frame: At Week 16 ]
    This is assessed for participants with ADerm-SS skin pain score >= 4 (MCID) at baseline.
  • Percentage of Participants Achieving an Improvement (Reduction) in Atopic Dermatitis Symptom Scale (ADerm-SS) 7-item Total Symptom Score (TSS-7) >= 28 (MCID) from Baseline [ Time Frame: At Week 16 ]
    This is assessed for participants with ADerm-SS TSS-7 >= 28 (MCID) at baseline.
  • Percentage of Participants Achieving an Improvement (Reduction) in ADerm-IS Emotional State Domain Score >= 11 (MCID) from Baseline [ Time Frame: At Week 16 ]
    This is assessed for participants with ADerm-IS emotional state domain score >= 11 (MCID) at Baseline.
  • Percentage of Participants Achieving an Improvement (Reduction) in ADerm-IS Daily Activities Score >= 14 (MCID) from Baseline [ Time Frame: At Week 16 ]
    This is assessed for participants with ADerm-IS daily activities score >= 14 (MCID) at baseline.
  • Percentage of Participants Achieving EASI 100 [ Time Frame: At Week 16 ]
    The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD.
Original Secondary Outcome Measures  ICMJE
 (submitted: June 22, 2018)
  • Proportion of participants achieving an improvement (reduction) in worst pruritus Numerical Rating Scale (NRS) ≥ 4 [ Time Frame: At Week 16 ]
    The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period.
  • Proportion of participants achieving EASI 90 [ Time Frame: At Week 16 ]
    The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD.
  • Proportion of participants achieving EASI 50 [ Time Frame: At Week 1 ]
    The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD.
  • Proportion of participants achieving an improvement (reduction) in worst pruritus Numerical Rating Scale (NRS) ≥ 4 for participants randomized to dose A [ Time Frame: At Day 2 ]
    The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period.
  • Proportion of participants achieving an improvement (reduction) in worst pruritus Numerical Rating Scale (NRS) ≥ 4 for participants randomized to dose B [ Time Frame: At Day 3 ]
    The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a daily recall period.
  • Proportion of participants achieving an improvement (reduction) in Atopic dermatitis impact scale (ADerm-IS) sleep domain score ≥ Minimal clinically important difference (MCID) [ Time Frame: At Week 16 ]
    This is assessed for participants with ADerm-IS sleep domain score ≥ MCID.
  • Proportion of participants achieving an improvement (reduction) in Atopic dermatitis symptom scale (ADerm-SS) skin pain score ≥ Minimal clinically important difference (MCID) [ Time Frame: At Week 16 ]
    This is assessed for participants with ADerm-SS skin pain score ≥ MCID.
  • Proportion of participants achieving an improvement (reduction) in Atopic dermatitis symptom scale (ADerm-SS) total score ≥ Minimal clinically important difference (MCID) [ Time Frame: Up to Week 16 ]
    This is assessed for participants with ADerm-SS total score ≥ MCID.
  • Proportion of participants achieving an improvement (reduction) in ADerm-IS total score ≥ Minimal clinically important difference (MCID) [ Time Frame: Up to Week 16 ]
    This is assessed for participants with ADerm-IS total score ≥ MCID.
  • Proportion of participants achieving EASI 100 [ Time Frame: At Week 16 ]
    The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD.
  • Proportion of participants achieving validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of 0 with a reduction of ≥ 2 points [ Time Frame: At Week 16 ]
    The vIGA-AD is a validated assessment instrument used in clinical studies to rate the severity of AD globally.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)
Official Title  ICMJE A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis
Brief Summary The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate to severe Atopic Dermatitis (AD) who are candidates for systemic therapy.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Atopic Dermatitis
Intervention  ICMJE
  • Drug: Upadacitinib
    It is administered orally.
    Other Names:
    • ABT-494
    • Rinvoq
  • Drug: Placebo for Upadacitinib
    It is administered orally.
Study Arms  ICMJE
  • Experimental: Arm A
    Upadacitinib Dose A is administered once daily.
    Intervention: Drug: Upadacitinib
  • Experimental: Arm B
    Upadacitinib Dose B is administered once daily.
    Intervention: Drug: Upadacitinib
  • Experimental: Arm C
    Placebo administered once daily followed by Upadacitinib Dose A once daily.
    Interventions:
    • Drug: Upadacitinib
    • Drug: Placebo for Upadacitinib
  • Experimental: Arm D
    Placebo administered once daily followed by Upadacitinib Dose B once daily.
    Interventions:
    • Drug: Upadacitinib
    • Drug: Placebo for Upadacitinib
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: October 7, 2020)
912
Original Estimated Enrollment  ICMJE
 (submitted: June 22, 2018)
810
Estimated Study Completion Date  ICMJE May 24, 2023
Estimated Primary Completion Date January 20, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Body weight of >= 40kg at Baseline Visit for participants between >= 12 and <18 years of age
  • Chronic atopic dermatitis (AD) with onset of symptoms at least 3 years before Baseline Visit
  • Active moderate to severe AD defined by Eczema Area and Severity Index (EASI), Investigator's Global Assessment (IGA), Body surface area (BSA), and pruritus
  • Candidate for systemic therapy or have recently required systemic therapy for AD
  • Documented history of inadequate response to topical corticosteroids (TCS) or topical calcineurin inhibitor (TCI) or documented systemic treatment for AD within 6 months before Baseline Visit

Exclusion Criteria:

  • Prior exposure to any Janus kinase (JAK) inhibitor
  • Unable or unwilling to discontinue current atopic dermatitis (AD) treatments prior to the study
  • Requirement of prohibited medications during the study
  • Other active skin diseases or skin infections requiring systemic treatment or would interfere with appropriate assessment of atopic dermatitis lesions
  • Female subject who is pregnant, breastfeeding, or considering pregnancy during the study
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 12 Years to 75 Years   (Child, Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Argentina,   Australia,   Bosnia and Herzegovina,   Bulgaria,   Canada,   China,   Colombia,   Croatia,   Denmark,   Estonia,   Finland,   France,   Germany,   Italy,   Japan,   Malaysia,   New Zealand,   Puerto Rico,   Romania,   Russian Federation,   Switzerland,   Turkey,   Ukraine,   United Kingdom,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03569293
Other Study ID Numbers  ICMJE M16-045
2017-005125-20 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Yes
Plan Description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting Materials: Study Protocol
Supporting Materials: Statistical Analysis Plan (SAP)
Supporting Materials: Clinical Study Report (CSR)
Time Frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.
Access Criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.
URL: https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html
Responsible Party AbbVie
Study Sponsor  ICMJE AbbVie
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: AbbVie Inc. AbbVie
PRS Account AbbVie
Verification Date October 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP